ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

On-and-off fasting helps fight obesity, study finds

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Low vitamin D levels predict ED in diabetics

What Benefits Can You Get From High-Quality Whey Protein?

 
Print Page
Email Article

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: A randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety – Source: BMC Medicine, Aug 16, 2010

  [ 14 votes ]   [ Discuss This Article ]
By Alan G Wade, et al. • www.ProHealth.com • August 20, 2010


[Note: To read the full text of this article free, click HERE.]

Background: Melatonin [in regular and timed release form] is extensively used in the USA in a non-regulated manner for sleep disorders.

Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over.

However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels.

The study investigated:

• Whether older age or low melatonin excretion is a better predictor of response to PRM,

• Whether the efficacy observed in short-term studies is sustained during continued treatment,

• And the long term safety of such treatment.

Methods: Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks) and then randomized, double-blind to 3 weeks with PRM or placebo nightly.

PRM patients continued whereas placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo run-out.

Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index (PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse effects and vital signs recorded at each visit.

Results:
On the primary efficacy variable sleep latency:

• The effects of PRM (3 weeks) in patients with low endogenous melatonin (6-sulphatoxymelatonin [6-SMT] 8 g/night) regardless of age did not differ from the placebo,

• Whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of melatonin levels (-19.1 versus -1.7 min; P=0.002).

• The effects on sleep latency - and additional sleep and daytime parameters that improved with PRM - were maintained or enhanced over the 6-month period with no signs of tolerance.

Most adverse events were mild in severity with no clinically relevant differences between PRM and placebo for any safety outcome.

Conclusions:
• The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients.

• Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia.

• The age cut-off for response warrants further investigation.

Source: BMC Medicine, Aug 16, 2010;8(1):51. PMID: 20712869, by Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. CPS Research and Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; Neurim Pharmaceuticals Ltd. and Department of Neurobiology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel. [Email: alangwade@fastmail.fm]





Post a Comment

Featured Products From the ProHealth Store
Melatonin Sublingual Tablets Mitochondria Ignite™ with NT Factor® FibroSleep™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Melatonin Sublingual Tablets Melatonin Sublingual Tablets
Supports Deep, Restful Sleep Naturally
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Joint Aches May Have Met Their Match in Curcumin Joint Aches May Have Met Their Match in Curcumin
Looking for Energy? Turn to Plants. Looking for Energy? Turn to Plants.
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map